Valuation : Nectar Lifesciences Limited

Market Cap 2.37B 25.08M 21.58M 20.31M 18.55M 34.7M 34.79M 240M 93.11M 1.21B 94.18M 92.13M 3.91B P/E 2025
-4.53x
P/E 2026 -0.69x
Enterprise Value 1.12B 11.83M 10.18M 9.58M 8.75M 16.37M 16.41M 113M 43.92M 573M 44.42M 43.46M 1.85B EV / Sales 2025
0.64x
EV / Sales 2026 -
Free-Float
44.34%
Yield 2025 *
-
Yield 2026 -
08-15 Nectar Lifesciences Limited Changes Its Corporate Office in Chandigarh CI
08-14 Nectar Lifesciences Limited Announces Board and Committee Changes, Effective August 14, 2026 CI
08-14 Nectar Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-06 Nectar Lifesciences Limited Announces Resignation of Dr. Surulichamy Senthilkumar from Non-Executive Non-Independent Director, Effective August 06, 2026 CI
07-11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
05-30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-05 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
03-02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
03-01 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
01-23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
01-05 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-19 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
1 day+0.16%
1 week-6.80%
Current month-2.79%
1 month+13.71%
3 months+0.91%
6 months+5.00%
Current year-37.20%
1 week 11.66
Extreme 11.66
12.93
1 month 10.05
Extreme 10.05
13.5
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 13/11/2022
Compliance Officer - 31/03/2025
Director TitleAgeSince
Chairman 66 26/06/1995
Director/Board Member 69 10/02/2019
Director/Board Member 75 20/09/2021
Date Insider Type Main position Quantity % Market Cap. Importance
19/12/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
+0.16%-6.80%-15.93%-53.91% 25.01M
-0.89%-0.75%+20.29%+71.24% 48.63B
-1.72%-1.23%+50.07%+117.58% 41.33B
-2.01%-5.82%+11.09%+82.43% 12.06B
-0.70%-2.46%-12.25%+11.21% 11.92B
+0.57%-0.56%+26.56%+153.11% 9.15B
+0.08%-4.11%+22.91%+43.56% 7.49B
-0.89%-0.93%+21.59%+221.93% 7.34B
-1.67%-0.31%+41.90%-11.56% 7.52B
-0.16%-2.87%-42.37%+14.21% 5.19B
Average -0.72%-1.54%+12.39%+64.98% 15.07B
Weighted average by Cap. -1.07%-0.41%+24.64%+84.92%

Financials

2025 2026
Net sales 16.7B 177M 152M 143M 131M 245M 245M 1.69B 657M 8.57B 664M 650M 27.61B -
Net income -1.14B -12.04M -10.36M -9.75M -8.9M -16.66M -16.7M -115M -44.7M -583M -45.21M -44.23M -1.88B -2.93B -31.02M -26.69M -25.12M -22.94M -42.92M -43.04M -297M -115M -1.5B -116M -114M -4.84B
Net Debt 5.62B 59.55M 51.24M 48.21M 44.04M 82.39M 82.62M 570M 221M 2.88B 224M 219M 9.29B -1.25B -13.25M -11.4M -10.73M -9.8M -18.33M -18.38M -127M -49.19M -642M -49.76M -48.67M -2.07B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
111
Date Price Change Volume
04/09/26 12.19 +0.16% 205,001
03/09/26 ₹12.17 -1.14% 274,924
02/09/26 ₹12.31 +1.48% 306,974
01/09/26 ₹12.13 -3.27% 284,172
31/08/26 ₹12.54 +0.56% 227,798
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock